This website is intended for healthcare professionals only

Trending Topic

16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]

44/Characterisation of missense variants in RYR2

DO Olubando (Presenting Author) – University of Manchester, Manchester, UK
< 1 min
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 4th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr44
Select a Section…
1

Article

The rare monogenic arrhythmogenic disorder catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterised by episodic ventricular dysrhythmia triggered by exercise or emotion in individuals without structural cardiac defects. Next generation sequencing has now become more widely accessible and RYR2 in its entirety can be screened relatively easily. This has led to an increase in the number of RYR2 variants being reported in individuals with cardiac dysrhythmia. The majority of RYR2 variants are missense changes that lead to increased channel activity and the rarity of these variants makes it difficult to determine their pathogenicity, thus the majority are classified as being of unknown significance (VUS). We collated RYR2 variants reported in individuals with or suspected of having CPVT and classified them using a statistical method and the ACMG guidelines. Where possible the phenotype associated with each variant was recorded to determine any genotype-phenotype correlations. Recently RYR2 variants have also been shown to cause ventricular arrhythmias by a loss of function mechanism. We used five computational splice prediction tools and an ex vivo splicing assay to investigate whether 329 rare variants in RYR2 from a cohort of individuals undergoing genetic testing for a ventricular arrhythmia alter splicing. Ten RYR2 variants were predicted to disrupt splicing by multiple computational tools. Of these, none altered splicing in an ex vivo splicing assay.

2

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup